Is the proposed exemption for pharmacies in H.R.971 one of those rare instances in which societal benefits from dispensing with antitrust rules and the normal competitive process exceeds the costs? In the Federal Trade Commission’s view, it is not.

-David Wales, Deputy Director of the FTC Bureau of Competition testifying before the Antitrust Task Force of the House Committee on the Judiciary